Sphera Funds Management’s PTC Therapeutics PTCT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q4
Sell
-118,345
Closed -$4.39M 126
2024
Q3
$4.39M Buy
118,345
+24,027
+25% +$804K 0.7% 47
2024
Q2
$2.88M Buy
+94,318
New +$3.06M 0.39% 70
2024
Q1
Sell
-136,525
Closed -$3.76M 119
2023
Q4
$3.76M Sell
136,525
-81,934
-38% -$1.87M 0.61% 59
2023
Q3
$4.9M Buy
218,459
+118,359
+118% +$4.4M 0.89% 41
2023
Q2
$4.07M Sell
100,100
-59,000
-37% -$2.89M 0.64% 56
2023
Q1
$7.71M Buy
+159,100
New +$7.27M 1.29% 23
2020
Q1
Sell
-214,736
Closed -$10.3M 93
2019
Q4
$10.3M Sell
214,736
-95,264
-31% -$4.05M 0.85% 19
2019
Q3
$10.5M Buy
+310,000
New +$13.5M 1.62% 14
2019
Q2
Sell
-220,500
Closed -$8.3M 108
2019
Q1
$8.3M Sell
220,500
-125,000
-36% -$4.2M 0.76% 24
2018
Q4
$11.9M Buy
345,500
+135,500
+65% +$4.87M 1.34% 19
2018
Q3
$9.87M Buy
+210,000
New +$8.69M 1.13% 20
2017
Q1
Sell
-150,000
Closed -$1.64M 124
2016
Q4
$1.64M Buy
+150,000
New +$1.57M 0.41% 64
2016
Q3
Sell
-174,461
Closed -$1.23M 116
2016
Q2
$1.23M Sell
174,461
-75,539
-30% -$554K 0.32% 73
2016
Q1
$1.61M Buy
250,000
+183,980
+279% +$3.19M 0.35% 65
2015
Q4
$2.14M Buy
66,020
+62,020
+1,551% +$1.83M 0.31% 81
2015
Q3
$107K Sell
4,000
-62,500
-94% -$2.67M 0.01% 126
2015
Q2
$3.2M Sell
66,500
-3,500
-5% -$204K 0.31% 81
2015
Q1
$4.26M Sell
70,000
-40,000
-36% -$2.44M 0.44% 56
2014
Q4
$5.7M Buy
110,000
+46,375
+73% +$2.04M 0.97% 28
2014
Q3
$2.8M Sell
63,625
-86,375
-58% -$2.7M 0.35% 70
2014
Q2
$3.92M Buy
+150,000
New +$3.21M 0.97% 31
2014
Q1
Sell
-73,583
Closed -$1.25M 130
2013
Q4
$1.25M Buy
+73,583
New +$1.29M 0.35% 67

Other funds holding PTCT

Sphera Funds Management's PTCT Position: Q4 2024 in Review

Sphera Funds Management sold out of PTC Therapeutics (PTCT) in Q4 2024, closing a stake of 118,345 shares — an estimated $4.39M sold.

Sphera Funds Management first reported a position in PTCT in Q4 2013 and held it in 22 quarters. The position peaked at $11.9M in Q4 2018. 240 funds tracked by Wall St. Rank hold PTCT as of Q4 2024.

  • Sphera Funds Management reported no remaining PTC Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Sphera Funds Management sold 118,345 PTC Therapeutics shares in Q4 2024, an estimated $4.39M.
  • Sphera Funds Management first reported a position in PTC Therapeutics in Q4 2013 and held it in 22 quarters.
  • Sphera Funds Management's PTC Therapeutics position peaked at $11.9M in Q4 2018.
  • 240 funds tracked by Wall St. Rank held PTC Therapeutics as of Q4 2024.

Based on Sphera Funds Management's 13F filing for Q4 2024, filed 14 Feb 2025.